Analyzing Bionano Genomics (NASDAQ:BNGO) and Epigenomics (OTCMKTS:EPGNY)

Epigenomics (OTCMKTS:EPGNY) and Bionano Genomics (NASDAQ:BNGO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Epigenomics and Bionano Genomics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Epigenomics	0	0	0	0	0.00
Bionano Genomics	1	0	1	0	2.00

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 404.20%. Given Bionano Genomics’ stronger consensus rating and higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Epigenomics.

Earnings and Valuation

This table compares Epigenomics and Bionano Genomics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Epigenomics	N/A	N/A	N/A	($3.05)	-0.78
Bionano Genomics	$30.18 million	0.46	-$26.40 million	($3.02)	-0.39

Epigenomics has higher earnings, but lower revenue than Bionano Genomics. Epigenomics is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

11.4% of Bionano Genomics shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Epigenomics and Bionano Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Epigenomics	N/A	N/A	N/A
Bionano Genomics	-106.58%	-78.78%	-48.54%

Summary

Bionano Genomics beats Epigenomics on 8 of the 11 factors compared between the two stocks.

About Epigenomics

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

About Bionano Genomics

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.